Thrombosis, or blood clotting, obstructs blood flow through the circulatory system and can be caused by numerous factors. Inflammation associated with SARS-CoV-2 or COVID-19 infection can lead to a type of thrombosis called "disseminated intravascular coagulopathy" (DIC) that affects the lung, heart, or kidneys. DIC in COVID-19 patients initially presents with abnormalities in prothrombin time, partial thromboplastin time, and platelet counts.

RayBiotech’s recombinant thrombin and thrombosis related proteins are ideal for developing coagulation assays to assist with DIC monitoring. The development of coagulation assays provides invaluable information not only about DIC, but about other hemostatic disorders as well and can be used to evaluate blood clotting during the development of drug therapeutics. Other causes of DIC include inflammation, infection, and cancer. Abnormal clots can also use up the blood’s clotting factors and lead to massive bleeding in other places.

Example SDS-PAGE of Recombinant Human Coagulation Factor II (F2 / Thrombin)

Purified proteins were untreated (Lane 2) or treated with deglycosylation under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.